Clinical Trial Update: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating perioperative nivolumab with or without relatlimab in patients with potentially resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING